Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 23;13:1006376. doi: 10.3389/fendo.2022.1006376

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Dinić, Arambašić Jovanović, Uskoković, Mihailović, Grdović, Tolić, Rajić, Đorđević and Vidaković

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Improvement of diabetic conditions by epigenome editing using CRISPR/dCas9 synthetic tools. The epigenome editing is cutting edge research tool for deciphering the pathology of diabetes and for offering a potential cure. The existing epigenetic editing tools are consisting of target DNA sequence recognition part (TALEN or dCas9) and linked to different effector domains (ED). ED could be any of epigenetic modifiers of DNA (DNMTs and TETs) or histones (histone modifying enzymes). In regard of diabetes treatment, several in vitro and in vivo studies based on usage of these tools have been recently released and are listed in the inset tables. gRNA-guide RNA.